Search the Newsreel

Earnings call transcript: Capri Global Capital posts strong Q1 2026 growth

Capri (CPRI) Expected to Post Quarterly Earnings on Wednesday

Capral (ASX:CAA): Can Earnings and Net Cash Narrow Its Discount to Asset Backing?

J Kumar Infraprojects Q1 Results: Earnings Call Scheduled for Aug 7

Capricor Therapeutics (CAPR) Falls On FDA Doubts, Where Does Fair Value Sit?

Aprea Therapeutics Inc (APRE) Financial Health: Profitability & Balance Sheet Analysis

Aprea Therapeutics Inc (APRE) currently holds a financial score of 6.51, ranking 248th out of 385 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The company's latest quarterly revenue decreased by 100.00% year-over-year, and net profit declined …

Aprea Therapeutics Inc (APRE) - Stock Score & Comprehensive Stock Analysis

This article provides a comprehensive stock analysis of Aprea Therapeutics Inc (APRE) by TradingKey, assigning it a score of 6.15/10. The analysis highlights the company's healthy fundamentals and significant growth potential, despite a recent weak stock market performance. It notes a high institutional ownership …

CAPR INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). The investigation concerns whether the Company and/or members of its senior management may have violated …

DJ Mediaprint & Logistics Ltd Revenue Breakdown – NSE:DJML

Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee Meeting – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP

Glancy Prongay Wolke & Rotter LLP has initiated a securities fraud investigation into Capricor Therapeutics, Inc. (CAPR) following a critical FDA review. The FDA's briefing documents raised concerns about the scientific justification and accuracy of Capricor's data collection for its cell therapy, concluding that …

CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation

Kehoe Law Firm, P.C. is investigating potential securities claims against Capricor Therapeutics, Inc. (NASDAQ:CAPR) after the company's stock price fell over 60% due to FDA concerns regarding the effectiveness data for its cell therapy, deramiocel. The FDA raised issues about Capricor changing how it …

Capricor Therapeutics: Downgrading To Sell As FDA Doubts Mount (NASDAQ:CAPR)

Capricor Therapeutics has been downgraded to Sell due to mounting FDA doubts regarding the efficacy of its lead product candidate, deramiocel, for DMD cardiomyopathy. The FDA noted that positive endpoints for their HOPE-3 trial were only achieved after post-unblinding SAP changes, compromising statistical validity. …

This Analyst Slashed CAPR Stock’s Target By 86% – But, Retail Bulls Say Setup Offers An Attractive Risk-Reward

Capri Holdings Ltd (CPRI) Institutional Confidence

Capri Holdings Ltd (CPRI) has an institutional shareholding score of 10.00, ranking 1st in the Specialty Retailers industry. The institutional shareholding proportion is 108.35%, indicating a 17.62% decrease quarter-over-quarter. David Einhorn is the largest institutional shareholder, holding 4.75 million shares.

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data

Capricor Therapeutics' shares fell after an FDA briefing document questioned the efficacy of its investigational cell therapy, Deramiocel, for Duchenne muscular dystrophy (DMD) ahead of a key FDA Advisory Committee meeting. The FDA stated that data from studies HOPE-3 and HOPE-2 did not provide …

FDA scientists question Capricor data; Legend CEO steps down

FDA scientists have expressed significant concerns over Capricor Therapeutics' data for its Duchenne muscular dystrophy cell therapy, causing the company's shares to drop sharply. Concurrently, Legend Biotech's CEO, Ying Huang, resigned amidst intense competition in the multiple myeloma market. Meanwhile, AstraZeneca reported mixed results …

Capri Holdings Ltd (CPRI) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Capri Holdings Ltd's (CPRI) dividend history and stock splits. It states that the company has distributed $0.00 in dividends over the past five years. The current stock price and market capitalization are also presented.

Capricor plunges on FDA AdCom briefing doc for Duchenne treatment

[Financial crisis down 3d red arrow economy business graph on money crash market background with bankruptcy decrease bad finance chart diagram or loss investment economic recession sales and low price.] Lemon_tm Capricor Therapeutics (CAPR [https://seekingalpha.com/symbol/CAPR]) is down ~67% in Monday morning trading after the …

Capricor Therapeutics shares tumble after FDA reviewers raise concerns over Duchenne therapy

Capricor Therapeutics shares fell by about 67% after FDA staff reviewers expressed concerns regarding the effectiveness of its experimental Duchenne muscular dystrophy therapy, deramiocel. The FDA questioned Capricor's analysis changes post-trial and raised doubts about whether study participants truly had DMD-related cardiomyopathy and if …

Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel

Capricor Therapeutics has issued comments regarding the FDA's briefing materials in anticipation of the upcoming Advisory Committee meeting on July 29, which will discuss the Biologics License Application (BLA) for Deramiocel, a treatment for Duchenne muscular dystrophy (DMD). The company asserts that the FDA's …

Capricor's Duchenne Therapy Heads To FDA Panel Review July 29; Stock Down

(RTTNews) - Capricor Therapeutics, Inc. (CAPR) is approaching a critical moment as the U.S. FDA's Cellular, Tissue, and Gene Therapies Advisory Committee convenes to review its Biologics License Application for Deramiocel, an investigational cell therapy for the treatment of Duchenne muscular dystrophy cardiomyopathy. Duchenne …

FDA staff flags data concerns about Capricor's therapy; shares plunge

U.S. FDA staff reviewers have raised significant concerns regarding the effectiveness data for Capricor Therapeutics' experimental cell therapy, deramiocel, intended for a heart condition associated with Duchenne muscular dystrophy. These concerns, centered on Capricor's methodology for measuring trial results and the scientific justification for …

SummitTX Capital L.P. Has $10.03 Million Holdings in Capri Holdings Limited $CPRI

SummitTX Capital L.P. significantly increased its stake in Capri Holdings Limited by 222.3% in the first quarter, now holding 569,054 shares valued at approximately $10.03 million. Other institutional investors also adjusted their positions in Capri, with 84.34% of the stock owned by such entities. …

Aprea Therapeutics Inc (APRE) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Aprea Therapeutics Inc.'s (APRE) shareholder structure, listing major individual and institutional holders and their percentage of ownership. It also presents a historical overview of institutional shareholding, showing changes in the number of institutions and shares held over …

Capricor Therapeutics shares plunge after FDA releases briefing documents

Capricor Therapeutics' shares plummeted 40% after the FDA released briefing documents for a cell therapy candidate aimed at Duchenne muscular dystrophy. The FDA highlighted the need for substantial evidence from at least two adequate clinical studies for approval, noting that Capricor's previous application based …

How FDA‑Linked HQ and Manufacturing Expansion At Capricor Therapeutics (CAPR) Has Changed Its Investment Story

Capri Global Capital posts ₹3,534M net profit in Q1FY26

Is Capricor Therapeutics (CAPR) Trading At A Discount After Its Lease Deal And FDA Wait?

Capricor Therapeutics Inc (CAPR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure and institutional holdings of Capricor Therapeutics Inc (CAPR). It lists major shareholders like Nippon Shinyaku Co Ltd and Suvretta Capital Management, LLC, along with a breakdown of shareholder types such as hedge funds and investment advisors. The article …

Capricor Therapeutics (CAPR) Secures New Headquarters Tied To FDA Decision On Deramiocel

Capricor Therapeutics (CAPR) has signed a lease for a new headquarters and expanded manufacturing facility, contingent on FDA approval of its Duchenne muscular dystrophy therapy, Deramiocel. This move signals the company's preparation for potential commercialization, with financial arrangements designed to phase in significant operating …

Aprea Therapeutics Inc (APRE) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Aprea Therapeutics Inc (APRE). It states that no dividends have been distributed in the past five years and details multiple stock splits that occurred on February 10, 2023, all listed as a 20-to-1 merger. …

1,349,826 Shares in Capri Holdings Limited $CPRI Bought by Cooper Creek Partners Management LLC

Cooper Creek Partners Management LLC purchased a significant stake of 1,349,826 shares in Capri Holdings Limited, valued at approximately $23.8 million, during the first quarter. This investment comes as Capri reported better-than-expected earnings per share but a substantial 23.1% year-over-year revenue decline. Analyst sentiment …

Capricor Therapeutics (CAPR) Stock Looks Fully Priced For Now

Capral Limited Revenue Breakdown – ASX:CAA

Aprea Therapeutics Inc APRE Cash Flow Statement

This article provides the quarterly and annual cash flow statements for Aprea Therapeutics Inc (APRE), detailing operating, investing, and financing cash flows. It also includes an overview of cash flow concepts and answers frequently asked questions regarding operating, investing, financing, and free cash flow …

This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy?

Key Points Karen Krasney, EVP, General Counsel, sold 24,100 common shares for a transaction value of ~$732,000 on June 25, 2026, at a weighted average price of around $30.38 per share. The transaction was executed through a derivative exercise (option exercise and immediate sale); …